Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
These press releases are intended for business journalists and analysts/investors
Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) - first, once-daily triple therapy for COPD reimbursed by the PBS in Australia
- 38th year of $80,000 research grant
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.